<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020358</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068299</org_study_id>
    <secondary_id>NCI-00-C-0216</secondary_id>
    <secondary_id>NCI-2391</secondary_id>
    <nct_id>NCT00020358</nct_id>
    <nct_alias>NCT00006287</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Melanoma</brief_title>
  <official_title>Randomized Comparison of Three Schedules of Peptide Immunization in Patients With Stage II or III, or Completely Resected Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Vaccine&#xD;
      therapy may be an effective treatment for melanoma.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of three vaccine therapy&#xD;
      regimens in treating patients who have melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the immunologic activity of three different schedules of peptide immunization&#xD;
           with gp100:209-217 (210M) or gp100:17-25 antigen and tyrosinase:368-376 (370D),&#xD;
           tyrosinase:240-251 (244S), tyrosinase:206-214 (closed to accrual 11/05/01), or&#xD;
           tyrosinase-related protein-1 (ORF3):1-9 peptide (closed to accrual 11/05/01) emulsified&#xD;
           in Montanide ISA-51 in patients with melanoma at high risk for recurrence.&#xD;
&#xD;
        -  Compare the response rate to treatment with interleukin-2 (IL-2) after being immunized&#xD;
           with this regimen with the usual response rate to IL-2 in this patient population.&#xD;
&#xD;
        -  Determine whether an exploratory cohort of HLA-A2-positive patients demonstrate&#xD;
           immunologic activity to immunization with 2 peptides emulsified together.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to HLA type (A0201 vs&#xD;
      A1 vs A3 vs A24 vs A31). (HLA-A24 and HLA-A31 closed to accrual 11/05/01). Patients are&#xD;
      randomized to 1 of 3 treatment arms and are given an assigned vaccine, which is emulsified in&#xD;
      Montanide ISA-51.&#xD;
&#xD;
        -  HLA typing:&#xD;
&#xD;
             -  HLA-A2: gp100:209-217 (210M) and tyrosinase:368-376 (370D)&#xD;
&#xD;
             -  HLA-A1: tyrosinase:240-251 (244S)&#xD;
&#xD;
             -  HLA-A3: gp100:17-25&#xD;
&#xD;
             -  HLA-A24: tyrosinase:206-214 (closed to accrual 11/05/01)&#xD;
&#xD;
             -  HLA-A31: tyrosinase-related protein-1 (ORF3):1-9 (closed to accrual 11/05/01)&#xD;
&#xD;
        -  Arm I: Patients receive assigned vaccine subcutaneously (SC) weekly for 10 weeks&#xD;
           followed by 3 weeks of no treatment.&#xD;
&#xD;
        -  Arm II: Patients receive assigned vaccine SC on days 1, 22, 43, and 64.&#xD;
&#xD;
        -  Arm III: Patients receive assigned vaccine SC on days 1-4, 22-25, 43-46, and 64-67.&#xD;
&#xD;
      Treatment in all arms repeats every 13 weeks for 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After the completion of the randomized arms of HLA-A2 patients, additional HLA-A2 patients&#xD;
      receive immunization with gp100:209-217 (210M) and tyrosinase:368-376 (370D) emulsified in&#xD;
      Montanide ISA-51 SC once every 3 weeks for 4 courses.&#xD;
&#xD;
      Patients with progressive disease may receive interleukin-2 IV over 15 minutes every 8 hours&#xD;
      for up to 4 days. Treatment repeats every 10-14 days for at least 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients with stable disease or mixed or&#xD;
      partial response to treatment may receive additional courses every 2 months.&#xD;
&#xD;
      Patients are followed at 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 324 patients (19-33 per arm for the HLA-A0201 stratum, 13-16&#xD;
      per arm for the other 4 strata, and 33 per the additional HLA-A2 cohort) will be accrued for&#xD;
      this study within 2 years. (HLA-A24 and HLA-A31 closed to accrual 11/05/01).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp100 antigen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of melanoma, including one of the following characteristics:&#xD;
&#xD;
               -  Lesions at least 1.5 mm in thickness&#xD;
&#xD;
               -  At least 1 positive lymph node&#xD;
&#xD;
               -  Ulcerated lesion&#xD;
&#xD;
               -  Local recurrence&#xD;
&#xD;
               -  Metastatic lesions completely resected within the past 6 months&#xD;
&#xD;
          -  Clinically disease free within the past 6 weeks&#xD;
&#xD;
          -  HLA-A1, A3, A24, A31, or 0201 positive (HLA-A24 and HLA-A31 closed to accrual&#xD;
             11/05/01)&#xD;
&#xD;
          -  No ocular or mucosal melanoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.6 mg/dL (3.0 mg/dL in Gilbert's syndrome)&#xD;
&#xD;
          -  AST and ALT less than 3 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  For interleukin-2 (IL-2) therapy:&#xD;
&#xD;
               -  No cardiac ischemia, myocardial infarction, or cardiac arrhythmias&#xD;
&#xD;
               -  Stress cardiac test required if abnormal EKG, symptoms of cardiac ischemia or&#xD;
                  arrhythmia, or older than 50 years&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  For IL-2 therapy:&#xD;
&#xD;
               -  No obstructive or restrictive pulmonary disease&#xD;
&#xD;
               -  FEV_1 greater than 60% predicted if prolonged history of cigarette smoking or&#xD;
                  symptoms of respiratory dysfunction&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infections, autoimmune disease, or active primary or secondary&#xD;
             immunodeficiency&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic biologic therapy for melanoma&#xD;
&#xD;
          -  No prior gp100 antigen or tyrosinase or TRP-1 peptide&#xD;
&#xD;
          -  No other concurrent systemic biologic therapy for melanoma&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic chemotherapy and recovered&#xD;
&#xD;
          -  No concurrent systemic chemotherapy for melanoma&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic endocrine therapy for melanoma&#xD;
&#xD;
          -  No concurrent systemic steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent systemic radiotherapy for melanoma&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005 Nov 1;175(9):6169-76.</citation>
    <PMID>16237114</PMID>
  </results_reference>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage I melanoma</keyword>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

